- Home
- AEE vs WAT Comparison
AEE vs WAT Comparison
Compare AEE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- WAT
- Stock Information
- Founded
- AEE 1901
- WAT 1958
- Country
- AEE United States
- WAT United States
- Employees
- AEE N/A
- WAT N/A
- Industry
- AEE Power Generation
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- AEE Utilities
- WAT Industrials
- Exchange
- AEE Nasdaq
- WAT Nasdaq
- Market Cap
- AEE 27.3B
- WAT 17.8B
- IPO Year
- AEE N/A
- WAT 1995
- Fundamental
- Price
- AEE $100.51
- WAT $299.57
- Analyst Decision
- AEE Buy
- WAT Hold
- Analyst Count
- AEE 11
- WAT 14
- Target Price
- AEE $102.82
- WAT $374.07
- AVG Volume (30 Days)
- AEE 1.3M
- WAT 582.9K
- Earning Date
- AEE 11-05-2025
- WAT 10-31-2025
- Dividend Yield
- AEE 2.82%
- WAT N/A
- EPS Growth
- AEE 2.91
- WAT 10.77
- EPS
- AEE 4.55
- WAT 11.09
- Revenue
- AEE $8,119,000,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- AEE $15.13
- WAT $7.19
- Revenue Next Year
- AEE $6.13
- WAT $6.40
- P/E Ratio
- AEE $22.14
- WAT $26.89
- Revenue Growth
- AEE 17.75
- WAT 5.89
- 52 Week Low
- AEE $82.95
- WAT $275.05
- 52 Week High
- AEE $104.10
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- AEE 51.42
- WAT 50.63
- Support Level
- AEE $98.72
- WAT $294.96
- Resistance Level
- AEE $101.17
- WAT $303.24
- Average True Range (ATR)
- AEE 1.03
- WAT 8.74
- MACD
- AEE -0.07
- WAT 0.56
- Stochastic Oscillator
- AEE 69.92
- WAT 54.47
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers accross its two service territories.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.